Sensitivity of White Blood Cell DNA to Damage from UV Light Distinguishes Cancer Patients from Healthy Individuals
By LabMedica International staff writers Posted on 13 Aug 2014 |

Image: The single cell gel electrophoresis assay or “comet” test (Photo courtesy of the Belgian BioElectroMagnetics Group).
A simple test that measures the extent of damage to white blood cell DNA caused by exposure to ultraviolet light has the potential to detect individuals with cancer before the appearance of any detectable symptoms.
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Latest Pathology News
- AI-Based Model Predicts Kidney Cancer Therapy Response
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more